Lupin Launches Generic Topiramate Capsules in US Market

announced the US launch of its topiramate extended-release capsules in 25 mg, 50 mg, 100 mg, and 200 mg strengths on February 4, 2026, following US FDA approval of its Abbreviated New Drug Application (ANDA). These capsules are bioequivalent to Supernus Pharmaceuticals' Trokendi XR and target epilepsy and migraine prevention, serving as initial monotherapy for partial-onset or primary generalized tonic-clonic seizures in patients aged 6+, adjunctive therapy for those seizures and Lennox-Gastaut syndrome in the same age group, and migraine prophylaxis for ages 12+. The US annual market for this product stands at $164 million, per IQVIA MAT December 2025 data, positioning it as a key generics opportunity for Lupin amid recent strategic moves like a TB drug collaboration. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.